Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

A meta-analysis showed risk for heart failure in men with prostate cancer receiving ADT was higher in Asian studies that in North American studies.

The treatment has become increasingly popular, especially among older men. Here is what to keep in mind if you are ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Announcing a new publication for Acta Materia Medica journal. Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men.

“Additionally, they called out the need for routine genetic testing of patients with advanced prostate cancer and emphatically called out the need for routine use of androgen deprivation therapy ...

Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising.

Prostate cancer (PrCa) is the most prevalent urogenital cancer affecting men. PrCa is marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic ...

Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Hormone therapy, which works by reducing the levels of testosterone in the body (a hormone that fuels the growth of prostate cancer cells), has long been a cornerstone of prostate cancer treatment.

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...